

**CLINICAL PRESENTATION AND TREATMENT OUTCOMES OF A RARE  
HEMATOLOGIC MALIGNANCY, SOLITARY PLASMACYTOMA: SINGLE CENTER  
EXPERIENCE**

**ABSTRACT**

**Aim:** Solitary plasmacytoma(SP) is a rare hematological malignancy. In our study, we aimed to present the clinical presentation of this disease and the effects of radiotherapy on local control and survival as a single center experience.

**Methodology:** Case records of patients diagnosed with solitary plasmacytoma treated in our clinic between 2010-2022 were evaluated retrospectively. Radiotherapy was planned with 3D Conformal technique and IMRT techniques. Kaplan-Meier method was used for survival analysis and Cox univariate regression analysis was used for comparison of other data.

**Results:** Thirty-five of 44 patients whose files were screened met the inclusion criteria. Of these, 26 (74.3%) were solitary bone plasmacytoma (SBP) and 9 (25.7%) were extramedullary plasmacytoma (EMP). The thoracic vertebrae were the most common sites of SBP, while EMP most frequently occurred in the upper respiratory tract. The most common symptoms were pain and spinal compression. Median follow-up was 46.9 months. Multiple myeloma developed in 12 patients (34.3%) and secondary malignancy developed in three patients (8.6%) during follow-up. 1, 3 and 5-year survival rates were 94%, 80% and 76% respectively; median progression-free survival was 34.4 months.

**Conclusion:** We think that this study, in which we shared the data of a single center in the rare disease group, contributes to the literature in terms of detecting prognostic factors and managing the treatment process more accurately. Our results can be supported by multicenter studies that will include a larger number of patients.

**Keywords:** Plasmacytoma, Radiotherapy, Treatment outcomes, Presentation

## INTRODUCTION

Solitary plasmacytoma (SP) is a localized and rare hematological neoplasm that accounts for 3% of all plasma cell neoplasms. The clinical presentation is in two different forms as solitary bone plasmacytoma (SBP) and solitary extramedullary plasmacytoma (SEP).

Its diagnosis requires with a plasma cell percentage in the bone marrow of <10%, along with imaging confirmation of a solitary tumour with no other evidence of organ or tissue damage and only minimal serum or urine level of monoclonal immunoglobulin [1-3]. Diagnostic analysis consists of physical examination, complete blood count, serum protein electrophoresis, evaluation of the urine for myeloma protein, skeletal survey and bone marrow biopsy.

Skeletal survey is beneficial to detect osteoblastic response to bone destruction. Low-dose whole body computed tomography can be used as an initial imaging technique for detecting small (<5mm) lytic bone lesions in especially patients with multiple myeloma [4, 5]. MRI is the gold standard for detecting soft tissue lesions, bone marrow involvement and spinal cord compression, especially diffusion-weighted MRI is a highly sensitive technique [3, 5, 6]. 18F-FDG (fluorine -18-fluorodeoxyglucose) PET/CT and <sup>99m</sup>Tc-MIBI are other imaging techniques used in diagnosis and evaluation of treatment response [3, 6, 7].

Our knowledge of prognosis is based on retrospective series. In small retrospective studies, risk factors for progression were reported as: bone localization (SBP), advanced age (>60), tumor size >5 cm, persistence of a paraprotein >1 year after treatment, and abnormal serum free light chain ratio at diagnosis [2, 8, 9]. Strong retrospective study results and prospective studies are needed to more accurately define the risk factors affecting prognosis.

Radiotherapy (RT) or/and surgery were the most used treatment modalities. Solitary plasmacytoma is highly radiosensitive tumor [9-11]. Surgery is controversial based on the results of

retrospective studies. LiQW et al. reported that the results of RT alone were superior to those of SP patients who underwent surgery alone [10, 12].

In this retrospective study, we examined the results of solitary plasmacytoma treated in a hospital with one of the largest oncology clinics in Turkey. We also aimed to identify risk factors for progression to myeloma, local control, and overall survival.

## **MATERIAL and METHODS**

### **Patients and Treatment Characteristics**

A retrospective analysis of cases with solitary plasmacytoma treated in a single center between 2010- 2022 was performed.

Inclusion criteria were: 1) histologically proven plasma cell tumor, 2) solitary bone plasmacytoma or solitary extrameduller plasmacytoma, 3) plasma cell percentage in the bone marrow of <10%, 5) being treated with external radiotherapy, with either 3D-Conformal or (Intensity modulated radiation therapy) IMRT or Volumetric arc therapy (VMAT) techniques;

Exclusion criteria were: 1) Previous history of radiotherapy for treatment area, 2) secondary malignancy at the time of treatment, 3) less than 3 months of follow up, 4) solitary tumor with evidence of organ or tissue damage. **In case of delay in the diagnosis of the disease, an increase in the existing tumor volume or transformation into multiple myeloma may occur. In case of an increase in tumor volume, only our treatment volume expands, and there is no difference in the administered dose. In the case of multiple myeloma transformation, the patients were not included in the study and were primarily referred to an oncologist.**

In all patients, physical examination, complete blood count, serum protein electrophoresis, evaluation of the urine for myeloma protein, skeletal survey, tissue and bone marrow biopsy were routinely performed, and in most patients, magnetic resonance imaging(MRI)/18-fluorodeoxglucose positron emission tomography(PET) was used.

The parameters evaluated in the study; age, sex, initial symptoms, extramedullary or bone origin, tumor size, tumor localization, treatment modality, surgical resection, radiotherapy technique and dose, treatment response rate with RECIST criteria and the effects of these factors on LPFS, MFS, DSS, OS were investigated.

Study was approved by the ethics committee of University of Health Sciences, Kartal Dr Lutfi Kirdar City Hospital 2022/514/160/2.

### **Radiotherapy Technique**

All patients were properly immobilized according to tumor localization. The thermoplastic head and neck mask was used for immobilization of tumor in the head and neck area and computed tomography (CT) images were taken in 2,5 mm slice thickness. Target volumes were delineated as follows: GTV (gross tumor volume): either primary tumour visible on CT/ MRI/ PET-CT. CTV (clinical target volume): 1-3 cm margin was applied to tumor according to tumor localization. PTV (planning target volume): 3-5 mm margin was applied to CTV. Critical structures were contoured according to the tumor site.

The IMRT plan was designed as three to nine fields technique and VMAT plan was designed as 2 to 4 arc technique. Plans were normalized so that 100 % of the PTV received more than 95% of the prescription dose. RTOG (radiation therapy oncology group) and QUANTEC (Quantitative analysis of normal tissue effect in the clinic) dose constraints were used to control critical structure doses in different anatomical locations. Different fractionation schemes were used (total dose/ fractions/ dose per fraction); (54-50-46- 40Gy/ 27-25-23-20fr / 2Gy); (30-36Gy/ 10-12fr/ 3Gy); (20Gy/ 5fr/ 4Gy), respectively.

Treatment area accuracy was evaluated by performing image guided radiotherapy using kV-kV images and /or cone beam CT every day or every other day throughout the entire treatment period.

### **Follow-up statistical analysis:**

During the treatment period acute toxicities were assessed weekly. Patients were examined at 1 and 3 months after the completion of radiotherapy for treatment-related toxicities, and every 3 months thereafter. RTOG/EORTC scales were used to assess acute and late side effects [13].

Data analysis was performed with SPSS (version 17.0; IBM, Armonk, USA). Local progression free survival (LPFS), myeloma free survival (MFS) and overall survival (OS), disease specific survival (DSS) rates were calculated using the Kaplan–Meier method. The LPFS rates were calculated from the last day of RT until either disease recurrence or progressive disease or death. MFS, DSS and OS was calculated from diagnosis until death or censoring at the last follow-up visit. Cox univariate regression analysis was performed to identify factors affecting survival. Statistical significance was set at  $p < 0.05$ .

## **RESULTS**

Thirty-five of 44 patients met the inclusion criteria and included in this analysis. Pain was the most common symptom in clinical presentation. Spinal compression, dyspnea, fracture and mass related complaints were other symptoms. Median follow-up was 46.9 months (range: 4.4-103 months). The median age was 62 years (range: 30–86). There were eight (22.8%) patients with solitary extramedullary plasmacytoma and twenty-seven (77.2%) with solitary bone plasmacytoma. The median time interval between the onset of multiple myeloma (MM) was 32.4 months (range: 2.7–103). Axial skeleton and upper respiratory tract (paranasal sinuses) were the most common sites of the solitary bone plasmacytoma and of solitary extramedullary plasmacytoma, respectively.

The median RT dose was 46 Gy (range: 20–54). Twenty three lesions (65.7%) were treated with high RT-doses ( $> 40$ Gy) [commonly applied in upper respiratory tract (nasal/paranasal localization)]. The other twelve lesions (34.3%) were treated with lower RT-doses up to 40 Gy (median: 30 Gy).

Ten patients (28.6%) received systemic therapies prior or after RT course. Patients, treatment and tumor characteristics are summarized in Table 1. and Table 2.

### **Overall and Disease Specific Survival**

Although eight patients had died at the time of the analysis, only four patients died due to plasma cell tumors. Four cases had died due to causes unrelated to plasma cell tumors (1 patients had secondary primary cancer, 2 had cardiovascular events, one patient died of an unknown cause with primary tumor under control at last control). The patients' time of death from unrelated plasma cell neoplasm were 4.4, 9, 37.5, 62.8 months, respectively. OS and DSS rates were 80% and 88.3%, respectively at 3 years (Figure 1). The estimated 5 and 8 year OS was 76%.

OS was significantly lower in patients older than fifty years old ( $p=0.045$ ). OS and DSS were 67.2%- 86.2% in the RT arm and 86-91.7% in the S+RT group in the 5th years, but no statistically significant difference was found between treatment modalities.

Tumor size  $\geq 5$  cm and the patient who underwent biopsy group had higher death rates than the others, but significant p value could not be detected.

Disease-specific survival was found to be significantly shorter in the patients who received a radiotherapy dose of  $<40$  Gy, ( $p=0.017$ ), but OS was not affected by the dose.

In treatment response assessment, OS rates at 5 year in  $>90\%$  response:(total or near total response)/90-stable:(responsible-stable disease)/progression groups were 95%, 54%, 0%, ( $P=0.022$ ); DSS was 100%, 85.7%, 0% ( $p=0.0001$ ), respectively.

As expected, DSS was found to be significantly shorter in patients who developed recurrence ( $p=0.001$ ) and patients who progress to myeloma ( $p=0.029$ ).

None of other treatment or disease characteristics had a significant impact on OS (gender, SBP or SEP type of plasmocytoma, localization, treatment modalities, surgical resection status, radiotherapy techniques, tumor size, progress to the myeloma;  $p>0,05$  for all comparisons). Prognostic factors affecting disease spesific survival and overall survival were detailed in Table 3.

Secondary cancers were seen in 2 (5.7%) cases; one was breast and the other one was lung cancer.

## **Disease control**

Isolated systemic recurrence was detected in 8 (22.8%) patients, both local and systemic recurrence in four (11.4%) patient. The 3- 5 year local progression free survival were 91 – 85.6%. Three and 5 year myeloma free survival rates were 74.3% and 53.7%, respectively.

LPFS and MFS were significantly better in the  $\leq 50$  years old group. LPFS was similar for patients treated radiotherapy or surgery+radiotherapy for five years (LPFS 88.2% vs. 84.4%,  $p>0.05$ ). Statistically significant factors affecting LPFS; tumor size  $\geq 5$  cm, radiotherapy dose  $<40$  Gy, response to treatment. Similarly gender, SEP or SBP, treatment modality, surgical resection type, radiotherapy technique had no statistically significant effect on local progression free survival ( $p>0.05$  for all comparisons). There was no progression to MF in the SEP group. Prognostic factors affecting local control and myeloma free survival were detailed in table 3. Three-5 years LPFS and MFS were 91-85.6 % and 74.3-53.7%. Patient who had undergone surgery prior to radiotherapy had a 5-year LPFS of 84.4% as compared to 88.2% in patient whose primary treatment was radiotherapy.

Similarly gender, sep or sbp, treatment modality, surgical resection type, radiotherapy technique had no statistically significant effect on local progression free survival ( $p>0.05$  for all comparisons). There was no progression to MF in the SEP group.

## **Systemic Therapy**

It was observed that chemotherapy was administered at different times and with different regimens in 10 (28.6%) cases. It was observed that systemic treatments were preferred in cases with bone marrow involvement or in cases where only biopsy or subtotal resection was performed in surgery. Bortezomib, lenolidamide or melphalan were utilized in systemic therapy. Using systemic therapy at any time in addition to RT and/or surgery did not contribute to LPFS, DSS, or OS ( $p>0.05$ ); It was observed that it contributed significantly to MFS ( $p=0.005$ ). In the subgroup analysis, the highest MFS rates were achieved with Lenolidamide, but no significant difference was found in terms of systemic treatment regimens ( $p=0.055$ ).

## **Side effects**

Grade 3-4 side effects were not observed in any patient.

## **DISCUSSION**

SBP and SEP are rare malignant plasma cell tumors. According to 2020 GLOBOCAN data, 176,404 (0.9%) newly diagnosed plasma cell tumors and 117,077 (1.2%) deaths due to these tumors have been reported under the title of multiple myeloma in the world. In our country, 2680 (1.1%) new cases and 1970 (1.6%) deaths were reported among all cancer diagnoses[14]. Due to the rarity of the patient group and the lack of prospective studies, we will try to discuss our study based on the results presented to us by the retrospective series.

The most common tumor localizations in the literature for SBP and SEP are the vertebral axis and head and neck region, respectively [1]. In our study, the frequency of tumor localizations was determined similarly. The clinical behavior of SBP and SEP differs. In the literature, more multiple myeloma progression and worse prognosis compared to SEP are reported in SBP cases. The results of our series also support the literature [3,15,16]. In solitary plasmacytoma, the MM progression rate has been reported to be 37-72% and the median progression time of 2 years [3,17]. In our study, the rate of progression to MM in our SBP cases was 44.4%, while no MM progression was found in our SEP cases.

Correct staging in diagnosis and correct use of imaging studies prevent misdiagnosis of SP and enable patients to reach the right treatment. The power of imaging tests used before and after 2001 in staging was emphasized in a study with a large patient series, and it was reported that myeloma may be subclinical in 40% of cases initially. According to the study, the progression rates of solitary plasmacytoma to MM after radiotherapy decreased over the years with the increase in the use of MRI and/or PET [18]. PET scanning is a helpful screening tool in order to examine the whole body in a single study and to clarify unclear CT or MRI abnormalities [19]. In our patient group, it was observed that the tests used in the staging of the disease were mostly PET-CT (34 pts) and/or MR (31 pts).

In a retrospective analysis of Sharpley et al. evaluating the modern era results in solitary plasmacytoma after 1986, they observed that progression to MM was inevitable in a group of patients, even though the 5-year OS was 90.7% and improved compared to previous series [3]. Considering the factors affecting prognosis, Katoditrou et al. (2014) found that there was no difference in survival between OS or PFS in SBP and EMP patient groups, but progression to MM and worse OS detected in patients aged >60 years and patients with short plasmacytoma free survival [3, 20, 21]. Similarly, in our patient group, LPFS, DSS and overall survival were not different in SBP and SEP patients, while MFS was found to be significantly shorter in the SBP group ( $p=0.032$ ). In the evaluation made in terms of age, MFS, DSS and OS were observed to be shorter in the age group >50 years, except for LPFS.

Tm size is another issue emphasized in the literature. In the study published in Princess Margaret Hospital by Tsang et al, in which they evaluated 46 cases in 2001, the tumor size range (0-18 cm, median 2.5 cm) was reported before radiotherapy, and local recurrence was reported to be more common in  $tm \geq 5$  cm group [3, 22]. The median tumor size detected by imaging techniques in our patients is 5cm (0.8-15cm). Evaluation was made by creating two groups with  $tm \geq 5$  cm and  $< 5$  cm, which are frequently emphasized in the literature. In our study, a trend supporting shorter LPFS was observed in cases with  $tm \geq 5$  cm, but no significant result could be obtained ( $p= 0.054$ ). In addition, it was found that tumor size did not affect MFS, DSS and OS, and it could not be shown to be a risk factor for progression to MM.

RT is the standard treatment in solitary plasmacytoma, besides, the tumor localization, tumor size, the relationship of the tumor with the surrounding tissue, and conditions requiring urgent intervention due to instability (neurological deficit, spinal compression) have been factors in the selection of other treatment options, such as surgery. [10, 23, 24]. For patients treated with gross tumor excision, RT is still indicated because of a high likelihood of microscopic residual disease [18]. Some studies have reported that local control is higher in patients in surgery plus radiotherapy [18, 25] and some studies have reported high control rates with only radiotherapy [26, 27]. In our series, no difference was observed between RT & surgery + RT in terms of recurrence, MFS, DSS, and OS.

In terms of radiotherapy technique, there was no difference between our results with the 3D-conformal technique and IMRT techniques. Regarding the radiotherapy dose, doses above 40 Gy were defined as radical doses in the literature, and doses of  $>40$  Gy were recommended even after surgical resection [3, 28]. Mendelhall et al. reported local recurrence results after  $\geq 40$  Gy and  $<40$  Gy as 6% versus 31% [28]. When  $\geq 40$  Gy and  $<40$  Gy doses were compared in our patient group; LPFS, MFS and DSS (0.003, 0.0001 and 0.017, respectively) rates were significantly worse in the group with treatment dose  $<40$  Gy. There was no difference between the doses in terms of OS.

Systemic chemotherapy in treatment is usually delayed until disease progression, and the role of chemotherapy during treatment is controversial. Katoditrou et al. think that chemotherapy does not affect survival and is toxic and of limited benefit [20]. It has been reported that there may be a limited contribution to MFS in the patient group receiving chemotherapy [29]. Finsinger et al. recommends chemotherapy after surgery/RT in SBP because of the high risk of progression to MM [16]. In our series, while the effect of chemotherapy applied at any part of the treatment on LPFS, DSS and OS was not observed, it was concluded that it could contribute significantly to MFS ( $p=0.005$ ).

In evaluation of treatment response; The importance of serum monoclonal M protein, especially after radiotherapy, has been shown in many studies in the literature. It has been emphasized that especially its detection/increase may indicate the conversion to MM [1, 5, 6, 23]. In our study, we reviewed the prognostic significance of the tumor's response to RT & RT+Surgery instead of monitoring the M protein level. There are currently no guidelines for the assessment of treatment responses in SP. In the literature, Caers et al. suggested using the RECIST criteria for evaluation of treatment response, but did not report prognostic results [5]. In our study, we first evaluated the response based on the RECIST criteria [30] and grouped them.  $>90\%$  tumor response (complete-near complete response), 90- stable disease (responsible-stable disease), progressive disease groups were evaluated. We found that LPFS, MFS, DSS, and OS were associated with worse survival times in cases that did not respond to treatment or progressed during treatment (Table 3).

## **CONCLUSION**

We think that this study, in which we shared the data of a single center in the rare disease group, contributes to the literature in terms of detecting prognostic factors and managing the treatment process more accurately. Our results can be supported by multicenter studies that will include a larger number of patients.

## REFERENCES

1. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. *ScientificWorldJournal*. 2012;2012:895765.
2. Xuxing Shen, Shu Liu, Chao Wu, Jing Wang, Jianyong Li, Lijuan Chen. Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population-based study. *Cancer Medicine*,2020, DOI: 10.1002/cam4.3533
3. Sharpley FA, Neffa P, Panitsas F, Kothari J, Subesinghe M, Cutter D, et al. Long term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. 2019;PLOS ONE 14(7):e0219857. <https://doi.org/10.1371/journal.pone.0219857>
4. Terpos E, Kleber M, Engelhardt M, Zweegman S, GayF, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. *Haematologica*. 2015;100:1254-66
5. Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma:updated recommendations from a European Expert Panel. *J Haematology & Oncology*. 2018, 11:10
6. Mouloupoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. *J Clin Oncol*. 1993;11:1311-5
7. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruziello F,et al.18F-FDG PET/CT, <sup>99m</sup>Tc-MIBI, and MRI in evaluationof patients with multiple myeloma. *J Nuclear Medicine:official publication, Society of Nuclear Medicine*. 2008;49(2):195-200. Epub2008/01/18.<https://doi.org/10.2967/jnumed.107.045641> PMID:18199607.
8. Agbuduwe C,Yang H,Gaglani J, Ajithkumar T.Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK. *Clinical Medicine*. 2020; 20 (5): e191-5 doi: 10.7861/clinmed.2019-0488

9. de Waal EGM, Leene M, Veeger N, et al. progression of solitary plasmacytoma to multiple myeloma. A population based registry of the northern Netherlands. *Br J Haematol* 2016;175:661-7
10. Thumallapally N, Meshref A, Mousa M, Terjanian T. Solitary plasmacytoma: population based analysis of survival trends and effect of various treatment modalities in the USA. *BMC Cancer* 2017;17(13):2-11 doi 10.1186/s12885-016-3015-5
11. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. *Oncology (Williston Park)*. 2000;14(1):101-8. 11; discussion 11-2, 15.
12. Li QW, Niu SQ, Wang HY, Wen G, Li YY, Xia YF, et al. Radiotherapy alone is associated with improved outcomes over surgery in the management of solitary plasmacytoma. *Asian Pac J Cancer Prev*. 2015;16(9): 3741-5
13. Cox JD, Stetz J, & Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). *International Journal of Radiation Oncology\* Biology\* Physics* 1995; 31(5): 1341-6
14. Hyuna Sung PhD, Jacques Ferlay MSc, ME, Rebecca L. Siegel MPH, Mathieu Laversanne MSc, Isabelle Soerjomataram MD, MSc, PhD, Ahmedin Jemal DMV, PhD, Freddie Bray BSc, MSc, PhD. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021; 71: 209-49  
<https://doi.org/10.3322/caac.21660>
15. El-Fattah MA, Aboelmagd M, Elhamouly M. Clinical risk factors of Plasmacytoma mortality: a US population-based study. *British journal of haematology*. 2017;179(1):161-2. Epub 2016/06/14. 10.1111/bjh.14189 .
16. Finsinger P, Grammatico S, Chisini M, Piciocchi A, Foa R, Petrucci MT. Clinical features and prognostic factors in solitary plasmacytoma. *British journal of haematology*. 2016;172(4):554-60. Epub 2015/12/20. 10.1111/bjh.13870
17. Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. *American journal of hematology*. 2012;87(7):647-51. Epub 2012/05/03. 10.1002/ajh.23201

18. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. *Int J Radiat Oncol Biol Phys* 2006;64(1):210–7.
19. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood* 2011;117(18):4701–5.
20. Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsolis MC, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. *American journal of hematology*. 2014;89(8):803–8. Epub 2014/04/24. 10.1002/ajh.23745.
21. Graça M. Dores,<sup>1,2,\*</sup> Ola Landgren,<sup>2</sup> Katherine A. McGlynn,<sup>2</sup> Rochelle E. Curtis,<sup>2</sup> Martha S. Linet,<sup>2</sup> and Susan S. Devesa<sup>2</sup>. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: Incidence and survival in the United States, 1992–2004. *Br J Haematol*. 2009 Jan; 144(1): 86–94. doi: 10.1111/j.1365-2141.2008.07421.x
22. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. *International journal of radiation oncology, biology, physics*. 2001;50(1):113–20. Epub 2001/04/24. 10.1016/s0360-3016(00)01572-8
23. Basavaiah SH, Lobo FD, Philipose CS, Suresh PK, Sreeram S, Kini H et al. Clinicopathological spectrum of solitary Plasmacytoma: a single center experience from coastal India. *BMC Cancer* 2019;19:801. <https://doi.org/10.1186/s12885-019-5976-7>
24. Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. *Br J Haematol* 2004;124(6):717–26.
25. Sasaki R, Yasuda K, Abe E, et al. Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. *Int J Radiat Oncol Biol Phys* 2012;82(2):626–34.

26. bataille R, sany J. Solitary myeloma :clinical and prognostic features of areview of 114 cases. *Cancer*. 1981;48:845-51
27. frassica da,frassica FJ,Schray MF,Sim FH, Kyle RA. Solitary plasmacytoma of bone:Mayo cliniv experience. *Int J Radiat Oncol Biol Phys*. 1989;16:43-8
28. Mendenhall CM, Thar TL, Million RR. Solitary plasmacytoma of bone and soft tissue. *International journal of radiation oncology, biology, physics*. 1980;6(11):1497–501. Epub 1980/11/01. 10.1016/0360-3016(80)90006-1.
29. Aviles A, Huerta-Guzman J, Delgado S, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. *Hematol Oncol* 1996;14(3):111–7.
30. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumors: revised RECIST guideline(version1.1) *Eur J Cancer*. 2009;45:228-47.

**Table 1:** Patients and treatment characteristics

Base line characteristics		Frequency	Percent
Age	Median 62 (30-86)	n	%
	≤ 50	8	22.9
	>50	27	77.1
Sex	Male	18	51.4
	Female	17	48.6
Treatment	Radiotherapy	18	22.9
	Surgery+Radiotherapy	17	48.6
Surgery	Biopsy	18	51.4
	Subtotal excision	7	20
	Total excision	10	28.6
Radiotherapy	Techniques		
	3D konformal	21	60
	IMRT/VMAT	14	40
	Dose		
	<40Gy	12	34.3
	≥ 40 Gy	23	65.7
Treatment Responce	90%(complete/near complete respose)	20	57.2
	90-stable disease(response+ /stable disease)	11	31.4
	Progression	4	11.4
Progression to Myeloma	Yes	12	34.3
	No	23	65.7
Local failure	Yes	4	11.4
	No	31	88.6

**Table 2:** Tumor characteristics

	n	%
Type		
Solitary bone plasmacytoma	27	74.3
Solitary extrameduller plasmacytoma	8	22.8
Tumor size		
< 5cm	16	45.7
≥ 5 cm	19	54.3
Localization		
Bone (SBP)	27	77.2
Axial skeleton	19	54.2
Apendiculer skeleton	8	22.8
Extrameduller (SEP)	8	22.8
Upper airway tract	5	14.3
Lung	1	2.9
Breast	1	2.9
Soft tissue	1	2.9

---

**Table 3:** Univariate Analysis for Prognostic factors affecting LPFS, MFS and DSS, OS

---

	Worse prognostic factors	LPFS	MFS	DSS	OS
Age	>50	NS	<b>0.0047</b>	<b>0.069</b>	<b>0.045</b>
Tumor size	≥5 cm	<b>0.054</b>	NS	NS	NS
SEP or SBP	SBP	NS	<b>0.032</b>	NS	NS
Radiotherapy dose	<40 Gy	<b>0.003</b>	<b>0.0001</b>	<b>0.017</b>	NS
Treatment response	>stable-progressive disease	<b>0.0001</b>	<b>0.0001</b>	<b>0.0001</b>	<b>0.022</b>

---

**Figure 1:** Survival curves of the patients.

